Literature DB >> 21052931

Current perspectives on the selective regulation of dopamine D₂ and D₃ receptors.

Dong Im Cho1, Mei Zheng, Kyeong-Man Kim.   

Abstract

Among the characterized dopamine receptor subtypes, D₂ receptor (D₂R) and D₃ receptor (D₃R) are the main targets of neuroleptics that are currently in use. In particular, D₃R is closely related to the etiology of schizophrenia and drug addiction. The spatial expression patterns of D₂R and D₃R are distinct in certain areas of the brain. D₂R are heavily expressed in the regions responsible for motor functions, whereas D₃R are more selectively expressed in the limbic regions, which are associated with cognitive and emotional functions. Therefore, disturbances in the motor and endocrine functions, which are the most serious problems caused by the current neuroleptics, are likely to result from the non-selective blockade of D₂R. Selective regulation of D₃R is needed to separate the desired therapeutic activities from unwanted side effects that result from promiscuous blockade of other receptors. D₂R and D₃R possess high sequence homology and employ similar signaling pathways, and it is difficult to selectively regulate them. In this review, we discuss the signaling mechanisms, intracellular trafficking, and desensitization properties of D₂R and D₃R. In addition, the proteins interacting with D₂R or D₃R are discussed in relation to their roles in the regulation of receptor functions, followed by the current status of the development of selective D₃R ligands.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21052931     DOI: 10.1007/s12272-010-1005-8

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  32 in total

1.  The N-terminal region of the dopamine D2 receptor, a rhodopsin-like GPCR, regulates correct integration into the plasma membrane and endocytic routes.

Authors:  D I Cho; C Min; K S Jung; S Y Cheong; M Zheng; S J Cheong; M H Oak; J H Cheong; B K Lee; K M Kim
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Selectivity and activation of dopamine D3R from molecular dynamics.

Authors:  Zhiwei Feng; Tingjun Hou; Youyong Li
Journal:  J Mol Model       Date:  2012-07-03       Impact factor: 1.810

Review 3.  Psychiatric drugs bind to classical targets within early exocytotic pathways: therapeutic effects.

Authors:  Henry A Lester; Julie M Miwa; Rahul Srinivasan
Journal:  Biol Psychiatry       Date:  2012-07-06       Impact factor: 13.382

Review 4.  Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.

Authors:  Amy E Moritz; R Benjamin Free; David R Sibley
Journal:  Cell Signal       Date:  2017-07-14       Impact factor: 4.315

5.  Novel roles for β-arrestins in the regulation of pharmacological sequestration to predict agonist-induced desensitization of dopamine D3 receptors.

Authors:  C Min; M Zheng; X Zhang; M G Caron; K M Kim
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

6.  Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R).

Authors:  Vivek Kumar; Amy E Moritz; Thomas M Keck; Alessandro Bonifazi; Michael P Ellenberger; Christopher D Sibley; R Benjamin Free; Lei Shi; J Robert Lane; David R Sibley; Amy Hauck Newman
Journal:  J Med Chem       Date:  2017-02-10       Impact factor: 7.446

7.  ARF6 and GASP-1 are post-endocytic sorting proteins selectively involved in the intracellular trafficking of dopamine D₂ receptors mediated by GRK and PKC in transfected cells.

Authors:  D I Cho; M Zheng; C Min; K J Kwon; C Y Shin; H K Choi; K M Kim
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

8.  Highly Selective Dopamine D3 Receptor Antagonists with Arylated Diazaspiro Alkane Cores.

Authors:  Sean W Reilly; Suzy Griffin; Michelle Taylor; Kristoffer Sahlholm; Chi-Chang Weng; Kuiying Xu; Daniel A Jacome; Robert R Luedtke; Robert H Mach
Journal:  J Med Chem       Date:  2017-11-21       Impact factor: 7.446

9.  Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist.

Authors:  Amy E Moritz; R Benjamin Free; Warren S Weiner; Emmanuel O Akano; Disha Gandhi; Ara Abramyan; Thomas M Keck; Marc Ferrer; Xin Hu; Noel Southall; Joseph Steiner; Jeffrey Aubé; Lei Shi; Kevin J Frankowski; David R Sibley
Journal:  J Med Chem       Date:  2020-05-12       Impact factor: 7.446

10.  Dopaminergic modulation of reward discounting in healthy rats: a systematic review and meta-analysis.

Authors:  Jaime J Castrellon; James Meade; Lucy Greenwald; Katlyn Hurst; Gregory R Samanez-Larkin
Journal:  Psychopharmacology (Berl)       Date:  2020-11-19       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.